Glutaminyl Cyclase, Diseases, and Development of Glutaminyl

Glutaminyl Cyclase, Diseases, and Development of Glutaminyl Cyclase Inhibitors

Therapeutic potential of glutaminyl cyclases: Current status and emerging trends - ScienceDirect

Frontiers Development and evolution of human glutaminyl cyclase inhibitors (QCIs): an alternative promising approach for disease-modifying treatment of Alzheimer's disease

Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation

Glutaminyl Cyclase, Diseases, and Development of Glutaminyl Cyclase Inhibitors

Glutaminyl Cyclase, Diseases, and Development of Glutaminyl Cyclase Inhibitors

RU2662559C1 - New inhibitor of glutaminyl cyclase and its use for treatment of lung and respiratory diseases - Google Patents

Identification of thyrotropin-releasing hormone as hippocampal glutaminyl cyclase substrate in neurons and reactive astrocytes - ScienceDirect

Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease–like pathology

a Glutaminyl cyclase activity (mU/L): change from baseline at end of

A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies

Glutaminyl cyclase inhibition leads to reduced binding of recombinant

Upregulation of Glutaminyl Cyclase Contributes to ERS-Induced Apoptosis in PC12 Cells

Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation